Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 2 Track A: Clinical Experience with Immune-Targeting Oligonucleotides and MicroRNAs

Session Chair(s)

Arthur M. Krieg, MD

Arthur M. Krieg, MD


Checkmate Pharmaceuticals, United States

Daniela  Verthelyi, MD, PhD

Daniela Verthelyi, MD, PhD

Chief, Laboratory of Immunology, OBP, OPQ, CDER

FDA, United States

Therapeutic oligonucleotides offer a remarkable breadth of mechanisms and applications aside from inducing the cleavage of a target mRNA. This session explores a few of these including activating anti-tumor immunity with CpG DNA through TLR9 or with RNA and regulating the function of microRNAs.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the immune pathways that can detect foreign RNA and DNA
  • Recognize how immune activation by DNA and RNA can trigger anti-tumor immunity
  • Understand how microRNAs can be modulated to regulate cell functions


Arthur M. Krieg, MD

Overcoming Resistance to Checkpoint Inhibition with Intratumoral or Systemic Injection of a CpG-A TLR9 Agonist

Arthur M. Krieg, MD

Checkmate Pharmaceuticals, United States


Mathias  Vormehr, PhD

Antitumoral T-Cell Immunity Triggered by Systemic RNA Lipoplex Vaccination in Cancer Patients

Mathias Vormehr, PhD

BioNTech RNA Pharmaceuticals GmbH, Germany

Head of Cancer Vaccines

Diana  Escolar, MD

Clinical Development of microRNA Inhibitors

Diana Escolar, MD

Miragen, United States

Senior Vice President Medical Science

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.